Segall Bryant & Hamill LLC Has $12.19 Million Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)

Segall Bryant & Hamill LLC cut its position in Blueprint Medicines Co. (NASDAQ:BPMC) by 1.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 139,743 shares of the biotechnology company’s stock after selling 1,879 shares during the quarter. Segall Bryant & Hamill LLC owned about 0.22% of Blueprint Medicines worth $12,188,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in BPMC. Empirical Asset Management LLC bought a new position in shares of Blueprint Medicines in the 4th quarter valued at about $2,348,000. Stephens Inc. AR acquired a new stake in Blueprint Medicines in the 4th quarter valued at about $321,000. Massachusetts Financial Services Co. MA grew its holdings in Blueprint Medicines by 48.8% during the third quarter. Massachusetts Financial Services Co. MA now owns 252,236 shares of the biotechnology company’s stock worth $23,332,000 after purchasing an additional 82,693 shares during the period. Bank of New York Mellon Corp increased its position in Blueprint Medicines by 2.4% during the fourth quarter. Bank of New York Mellon Corp now owns 303,432 shares of the biotechnology company’s stock worth $26,465,000 after buying an additional 7,101 shares during the last quarter. Finally, KBC Group NV raised its stake in Blueprint Medicines by 63.9% in the fourth quarter. KBC Group NV now owns 2,625 shares of the biotechnology company’s stock valued at $229,000 after buying an additional 1,023 shares during the period.

Blueprint Medicines Price Performance

Shares of BPMC stock opened at $93.08 on Wednesday. Blueprint Medicines Co. has a twelve month low of $80.68 and a twelve month high of $121.90. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. The business has a fifty day simple moving average of $99.12 and a 200 day simple moving average of $93.97. The company has a market cap of $5.95 billion, a P/E ratio of -86.18 and a beta of 0.58.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. On average, sell-side analysts forecast that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

Insider Buying and Selling at Blueprint Medicines

In other Blueprint Medicines news, insider Ariel Hurley sold 2,250 shares of the stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $100.00, for a total value of $225,000.00. Following the completion of the transaction, the insider now directly owns 14,967 shares in the company, valued at approximately $1,496,700. This trade represents a 13.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jeffrey W. Albers sold 5,000 shares of the business’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $102.28, for a total value of $511,400.00. Following the sale, the director now owns 157,557 shares in the company, valued at approximately $16,114,929.96. This trade represents a 3.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 29,334 shares of company stock worth $3,103,512 over the last quarter. Corporate insiders own 4.21% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on BPMC shares. Piper Sandler lifted their price objective on shares of Blueprint Medicines from $109.00 to $119.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Wedbush reaffirmed an “outperform” rating and set a $128.00 target price on shares of Blueprint Medicines in a report on Friday, February 28th. Needham & Company LLC reissued a “buy” rating and issued a $133.00 price target on shares of Blueprint Medicines in a report on Thursday, February 13th. JPMorgan Chase & Co. increased their target price on Blueprint Medicines from $126.00 to $129.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 4th. Finally, Stephens restated an “overweight” rating and issued a $140.00 price target on shares of Blueprint Medicines in a research note on Thursday, January 2nd. Two analysts have rated the stock with a sell rating, six have issued a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $124.95.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.